ArticleWorld journal of oncology2026
LINC01121 Is Associated With Prognosis and Facilitates the Proliferation, Migration, and Invasion of Colorectal Cancer.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of LINC01121 in the pathogenesis and prognosis of colorectal cancer (CRC) remains unknown. This study aimed to explore the function of LINC01121 in CRC development. Methods: Transcriptome expression data from The Cancer Genome Atlas (TCGA) database were utilized to investigate the relationship between LINC01121 and CRC prognosis through survival analysis. Samples from CRC patients and adjacent tissues were collected and analyzed to assess the expression differences between tumor and adjacent tissues. Functional assays such as Cell Counting Kit-8 (CCK8), EdU, scratch test, and Transwell assay were employed to determine the oncogenic role of LINC01121 in CRC cells. Additionally, gene enrichment analyses and immune infiltration analyses were conducted with R package. Results: The LINC01121 level was obviously higher in CRC tissues. The receiver operating characteristic (ROC) curve suggests that LINC01121 has significant diagnostic capabilities (area under the curve (AUC) = 0.659). High expression of LINC01121 predicted poor overall survival (OS) (P = 0.022), progression-free interval (PFI) (P = 0.007), and disease-specific survival (DSS) (P = 0.006). Gene Set Enrichment Analysis (GSEA) demonstrated that LINC01121-associated CRC encompasses various crucial pathways linked to tumorigenesis. The immune infiltration analyses revealed that LINC01121 may be involved in immune suppression. Conclusion: LINC01121 exhibits elevated expression in CRC and correlates with unfavorable prognosis and reduced immune infiltration in CRC patients. These findings suggest that LINC01121 may serve as a potential marker for the diagnosis and prognosis of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.